Business Description
ISIN : US81663L2007
Share Class Description:
WGS: Ordinary Shares - Class ATotal Employee Number:
1,300Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.79 | |||||
Equity-to-Asset | 0.51 | |||||
Debt-to-Equity | 0.69 | |||||
Debt-to-EBITDA | -2.41 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 3.25 | |||||
Beneish M-Score | -2.26 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -13.3 | |||||
3-Year Book Growth Rate | -21.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 20.92 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 81.3 | |||||
9-Day RSI | 76.05 | |||||
14-Day RSI | 71.75 | |||||
3-1 Month Momentum % | 19.54 | |||||
6-1 Month Momentum % | -27.38 | |||||
12-1 Month Momentum % | -53.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.3 | |||||
Quick Ratio | 3.06 | |||||
Cash Ratio | 1.78 | |||||
Days Inventory | 34.89 | |||||
Days Sales Outstanding | 55.24 | |||||
Days Payable | 13.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -35.4 | |||||
Shareholder Yield % | -2.18 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 69.37 | |||||
Operating Margin % | -12.96 | |||||
Net Margin % | -23.41 | |||||
EBITDA Margin % | -15.27 | |||||
FCF Margin % | -16.68 | |||||
OCF Margin % | -10.72 | |||||
ROE % | -38.65 | |||||
ROA % | -21.54 | |||||
ROIC % | -19.11 | |||||
3-Year ROIIC % | -1480.49 | |||||
ROC (Joel Greenblatt) % | -109.95 | |||||
ROCE % | -23.6 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 921.28 | |||||
PS Ratio | 5.81 | |||||
PB Ratio | 11.02 | |||||
Price-to-Tangible-Book | 26.56 | |||||
EV-to-EBIT | -28.34 | |||||
EV-to-Forward-EBIT | -27.2 | |||||
EV-to-EBITDA | -39.32 | |||||
EV-to-Revenue | 6 | |||||
EV-to-Forward-Revenue | 5.67 | |||||
EV-to-FCF | -36 | |||||
Price-to-GF-Value | 1.22 | |||||
| Price-to-Net-Current-Asset-Value | 291.35 | |||||
Earnings Yield (Greenblatt) % | -3.53 | |||||
FCF Yield % | -2.81 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:WGS
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
GeneDx Holdings Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 454.426 | ||
| EPS (TTM) ($) | -3.64 | ||
| Beta | 1.777 | ||
| 3-Year Sharpe Ratio | 1.07 | ||
| 3-Year Sortino Ratio | 2.59 | ||
| Volatility % | 76.71 | ||
| 14-Day RSI | 71.75 | ||
| 14-Day ATR ($) | 4.910428 | ||
| 20-Day SMA ($) | 77.728 | ||
| 12-1 Month Momentum % | -53.19 | ||
| 52-Week Range ($) | 32.21 - 170.87 | ||
| Shares Outstanding (Mil) | 29.82 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GeneDx Holdings Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GeneDx Holdings Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-23 08:30 | In 181 days | ||
| Annual report for 2026 | 2027-02-23 | In 180 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-23 | In 180 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-28 08:30 | In 63 days | ||
| Third quarter earnings results for 2026 | 2026-10-28 | In 62 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-03 16:30 | 65.11 (-6.88%) | ||
| Second quarter earnings results for 2026 | 2026-08-03 | 65.11 (-6.88%) | ||
| General meeting for 2026 | 2026-06-18 09:00 | 56.42 (-6.74%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 08:00 | 51.80 (-1.65%) | ||
| First quarter earnings conference call for 2026 | 2026-05-04 16:30 | 65.38 (+3.12%) |
GeneDx Holdings Corp Frequently Asked Questions
Guru Commentaries on NAS:WGS
GeneDx is a provider of genomic testing and diagnostics, using advanced sequencing technology to help clinicians diagnose rare diseases and inform treatment decisions. Despite the company continuing to report solid revenue growth and improving profitability, there has been some variability in testing volumes and reimbursement dynamics, which created modest uncertainty. Additionally, broader volatility across high-growth healthcare names has weighed on sentiment, leading to a decision to scale back exposure to GeneDx in the portfolio.
GeneDx is a specialty laboratory focused on genetic testing for the diagnosis of rare diseases, primarily targeting pediatric patients in neonatal intensive care units and those with developmental disorders. The company reported strong fiscal fourth-quarter results, driven by robust customer demand. Additionally, management raised their fiscal 2025 revenue guidance, exceeding analyst estimates, which indicates a positive outlook for the company's growth trajectory.
GeneDx is a specialty laboratory focused on genetic testing for the diagnosis of rare diseases, primarily targeting pediatric patients in neonatal intensive care units and those with developmental disorders. The company reported strong fiscal fourth-quarter results, driven by robust customer demand. Additionally, management raised their fiscal 2025 revenue guidance, exceeding analyst estimates, which indicates a positive outlook for the company's growth trajectory.
GeneDx is a specialty laboratory focused on genetic testing for the diagnosis of rare diseases, primarily targeting pediatric patients in neonatal intensive care units and those with developmental disorders. The company reported strong fiscal fourth-quarter results, driven by robust customer demand. Additionally, management raised their fiscal 2025 revenue guidance, exceeding analyst estimates, which indicates a positive outlook for the company's growth trajectory.
Press Release
Articles on GeneDx Holdings Corp
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
